Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody
Tóm tắt
Từ khóa
Tài liệu tham khảo
Thomas, D.L. Global control of hepatitis C: where challenge meets opportunity. Nat. Med. 19, 850–858 (2013).
Evans, M.J. et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446, 801–805 (2007).
Cohen, C.J. et al. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc. Natl. Acad. Sci. USA 98, 15191–15196 (2001).
Fukumatsu, M. et al. Shigella targets epithelial tricellular junctions and uses a noncanonical clathrin-dependent endocytic pathway to spread between cells. Cell Host Microbe 11, 325–336 (2012).
Che, P., Tang, H. & Li, Q. The interaction between claudin-1 and dengue viral prM/M protein for its entry. Virology 446, 303–313 (2013).
Mercer, D.F. et al. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7, 927–933 (2001).
Fofana, I. et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 139, 953–964 (2010).
Law, M. et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14, 25–27 (2008).
Lupberger, J. et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 17, 589–595 (2011).
Meuleman, P. et al. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 55, 364–372 (2012).
Shi, N. et al. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut 62, 1055–1061 (2013).
Harris, H.J., Wilson, G.K., Hubscher, S.G. & McKeating, J.A. Heterogeneous claudin-1 expression in human liver. Hepatology 57, 854–855 (2013).
Fletcher, N.F. et al. Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Hepatology 59, 1320–1330 (2014).
Bukh, J. et al. Challenge pools of hepatitis C virus genotypes 1–6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. J. Infect. Dis. 201, 1381–1389 (2010).
Pietschmann, T. et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. USA 103, 7408–7413 (2006).
Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791–796 (2005).
Fofana, I. et al. Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology 143, 223–233 (2012).
Krieger, S.E. et al. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2–CD81-claudin-1 associations. Hepatology 51, 1144–1157 (2010).
Harris, H.J. et al. Claudin association with CD81 defines hepatitis C virus entry. J. Biol. Chem. 285, 21092–21102 (2010).
Suh, Y. et al. Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene 32, 4873–4882 (2013).
Brazzoli, M. et al. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J. Virol. 82, 8316–8329 (2008).
Diao, J. et al. Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J. Virol. 86, 10935–10949 (2012).
Zona, L. et al. HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe 13, 302–313 (2013).
Menzel, N. et al. MAP-kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles. PLoS Pathog. 8, e1002829 (2012).
Wieland, S. et al. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology 59, 2121–2130 (2014).
Neumann, A.U. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282, 103–107 (1998).
Lan, L. et al. Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner. J. Immunol. 181, 4926–4935 (2008).
Haid, S. et al. Isolate-dependent use of Claudins for cell entry by hepatitis C virus. Hepatology 59, 24–34 (2014).
Fofana, I. et al. Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies. J. Virol. 87, 10405–10410 (2013).
Reynolds, G.M. et al. Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology 47, 418–427 (2008).
Koutsoudakis, G., Herrmann, E., Kallis, S., Bartenschlager, R. & Pietschmann, T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J. Virol. 81, 588–598 (2007).
Harris, H.J. et al. CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J. Virol. 82, 5007–5020 (2008).
Piche, T. et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 58, 196–201 (2009).
Zahid, M.N. et al. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology 57, 492–504 (2013).
Petersen, J. et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat. Biotechnol. 26, 335–341 (2008).